Delivery Order SPE2DR25D3301-SPE2DR26F18PP
- Not listed
- The Defense Logistics Agency awarded a $3,070.07 delivery order to AmerisourceBergen Drug Corp on October 29, 2025, for the supply of Zepbound 10 mg/0.5 mL pens (semaglutide injection). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of October 30, 2025. The products will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major...
- The Defense Logistics Agency awarded a $1,525.20 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with an ultimate completion date of August 19, 2025. The work is to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a small transaction within the...
- The Defense Logistics Agency awarded a delivery order valued at $1,566.07 to AmerisourceBergen Drug Corp for Zepbound 15 mg/0.5 ml pen (semaglutide injection), with an ultimate completion date of December 30, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $4,451.71 delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of November 7, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency awarded a $43,449.54 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 ml pen injectors on September 24, 2025, with a completion date of September 25, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order represents a single-transaction purchase under the company's broader relationship with the...
- The Defense Logistics Agency awarded a $3,962.03 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections on November 14, 2025, with completion targeted for November 17, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under the company's broader...
- The Defense Logistics Agency awarded a $13,137.57 delivery order to AmerisourceBergen Drug Corp on October 24, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 ml pen injections. This competitively awarded, firm fixed-price contract is set to conclude on October 27, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. As a non-set-aside procurement, the award reflects AmerisourceBergen's continued role as a critical pharmaceutical supplier within the federal...
- The Defense Logistics Agency awarded a $16,297.57 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 14, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's demonstrated...
- The Defense Logistics Agency awarded a delivery order valued at $7,848.75 to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injectors. This competitive, firm fixed-price delivery order is scheduled for completion by August 21, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a single transaction under the company's larger pharmaceutical supply framework with the federal...
- The Defense Logistics Agency awarded a delivery order valued at $2,839.82 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injectors on November 26, 2025, with completion targeted for November 28, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical...
- SPE2DR25D3301Indefinite Delivery Contract
- SPE2DR25D3301-SPE2DR26F18PPDelivery Order
The Defense Logistics Agency awarded a $13,438.83 firm fixed price delivery order to AmerisourceBergen Drug Corp on November 25, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens (semaglutide injection). The contract, which was competitively awarded with no set-aside designation, is scheduled for completion by November 26, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction under AmerisourceBergen's larger federal pharmaceutical supply framework with the federal government. This award is a child order issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal medical procurement across the Defense Health Agency, U.S. Coast Guard, and military healthcare systems. The company's contract portfolio demonstrates extensive capability in delivering brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to support military and veteran healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.4k | 11/24/25 |